Target Name: RBL2
NCBI ID: G5934
Review Report on RBL2 Target / Biomarker Content of Review Report on RBL2 Target / Biomarker
RBL2
Other Name(s): RB transcriptional corepressor like 2 | BRUWAG | Rb2 | P130 | PRB2 | RBL2 variant 1 | RBR-2 | pRb2 | retinoblastoma-related protein 2 | Retinoblastoma-related protein 2 | RB transcriptional corepressor like 2, transcript variant 1 | Retinoblastoma-like protein 2 | RBL2_HUMAN | retinoblastoma-like 2 | p130 | 130 kDa retinoblastoma-associated protein | Retinoblastoma-like protein 2 (isoform 1)

Understanding RBL2: A Potential Drug Target and Biomarker

RBL2 (RNA-binding protein like 2) is a protein that plays a crucial role in regulating gene expression in various organisms, including humans. It is a member of the RNA-binding protein superfamily and is found in various tissues and cells throughout the body. RBL2 is known to interact with other proteins, including RNA-protein interactions, which are crucial for the regulation of gene expression.

The search for potential drug targets and biomarkers is an important area of research in the pharmaceutical industry. Many drugs that are currently used to treat various diseases are based on the inhibition of specific protein interactions, which can lead to a better understanding of the underlying biology of the disease and the development of new treatments.

RBL2 is a protein that has been identified as a potential drug target and may be a biomarker for various diseases. In this article, we will explore the biology of RBL2, its potential drug target status, and its potential as a biomarker.

Biography of RBL2

RBL2 is a 21-kDa protein that is expressed in various tissues and cells throughout the body. It is a member of the RNA-binding protein superfamily and is characterized by the presence of a nucleotide-binding oligomerization domain (NBO), which is responsible for the interaction of RBL2 with RNA-prots.

RBL2 is involved in the regulation of gene expression by binding to specific RNA molecules. It has been shown to interact with various proteins, including RNA-prots, which are crucial for the regulation of gene expression. These interactions are regulated by various factors, including the concentration of RNA molecules, the presence of other proteins, and the chemical context of the interaction.

Potential Drug Target

RBL2 has been identified as a potential drug target due to its involvement in the regulation of gene expression. Many drugs that are currently used to treat various diseases are based on the inhibition of specific protein interactions, which can lead to a better understanding of the underlying biology of the disease and the development of new treatments.

One of the potential drug targets for RBL2 is the treatment of cancer. Cancer is a disease that is characterized by the rapid and uncontrolled growth of cells, which can lead to various types of cancer. The regulation of gene expression is a key factor in the development and progression of cancer, and RBL2 is involved in this regulation.

In addition to cancer, RBL2 has also been identified as a potential drug target for the treatment of neurodegenerative diseases, such as Alzheimer's disease. neurodegenerative diseases are characterized by the progressive loss of brain cells and are often treated with drugs that aim to slow down or halt the progression of the disease.

Potential Biomarker

RBL2 may also be used as a biomarker for various diseases. As a protein that is involved in the regulation of gene expression, RBL2 may be used to monitor the effectiveness of drugs that are designed to treat various diseases. For example, if an drug is able to inhibit the interaction of RBL2 with RNA-prots, it may be possible to use RBL2 as a biomarker to assess the effectiveness of the drug.

In addition to its potential use as a drug target, RBL2 may also be used as a biomarker for certain diseases. For example, RBL2 has been shown to be involved in the regulation of gene expression in various diseases, including cancer, neurodegenerative diseases, and genetic disorders.

Conclusion

In conclusion, RBL2 is a protein that has been identified as a potential drug target and may also be a biomarker for various diseases. Its involvement in the regulation of gene expression makes it an attractive target for the development of new treatments. Further research is needed to fully understand the role of RBL2 in the regulation of gene expression and its potential as a drug

Protein Name: RB Transcriptional Corepressor Like 2

Functions: Key regulator of entry into cell division. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters. Potent inhibitor of E2F-mediated trans-activation, associates preferentially with E2F5. Binds to cyclins A and E. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. May act as a tumor suppressor

The "RBL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3